UNIQURE
Live / Registered — Registered and renewed (as of 27 Jan 2025)
What this means for you
Registered since 31 Mar 2015. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 31 Mar 2025).
Record
- Serial number
- 85907857
- Registration number
- 4710280
- Mark type
- Stylized text
- Filed
- 18 Apr 2013
- Published for opposition
- 02 Sept 2014
- Registered
- 31 Mar 2015
- Next maintenance due
- 31 Mar 2025
- Attorney of record
- Julianne Abelman
Goods and services
- Class 001 — Chemicals: [Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes]
- Class 005 — Pharmaceuticals: Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viral vectors, [non-viral vectors,] gene therapy vectors, nucleic acid delivery vectors, [and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors] for medical purposes all for medical treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] pharmaceutical preparations and substances for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers;] biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy [and cell therapy,] all for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,]inherited disorders, genetic disorders, single gene disorders [and cancers;] [clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other] pharmaceutical preparations [all] for use in nucleic acid-based therapy, gene therapy [and cell therapy] in the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases,] inherited disorders, genetic disorders, single gene disorders [and cancers]
- Class 042 — Scientific and technological services: Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry
- Class 044 — Medical, beauty and agricultural services: Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, [ocular disorders,] diseases of the nervous system, blood disorders, liver disorders, [muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders,] inherited disorders, genetic disorders and single gene disorders
Owner
- UNIQURE BIOPHARMA B.V., AMSTERDAM, NL
- uniQure IP B.V., Amsterdam, NL
- uniQure IP B.V., Amsterdam, NL
- uniQure IP B.V., Amsterdam, NL
Prosecution history
- 11 Jun 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 04 Jun 2025 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 04 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Jun 2025 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 04 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Jun 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 27 Jan 2025 — NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
- 27 Jan 2025 — REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
- 27 Jan 2025 — REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
- 27 Jan 2025 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 04 Oct 2024 — TEAS SECTION 8 & 9 RECEIVED
- 31 Mar 2024 — COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
- 01 Apr 2021 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED